Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 27.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,531 shares of the biotechnology company’s stock after purchasing an additional 4,238 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Arrowhead Pharmaceuticals were worth $598,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Washington Trust Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $25,000. Fifth Third Bancorp lifted its holdings in shares of Arrowhead Pharmaceuticals by 112.0% in the 3rd quarter. Fifth Third Bancorp now owns 988 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 522 shares during the period. Friedenthal Financial acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $51,000. Van ECK Associates Corp grew its holdings in Arrowhead Pharmaceuticals by 22.9% during the fourth quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 447 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in Arrowhead Pharmaceuticals by 96.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,753 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 1,352 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Citigroup raised their price objective on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, February 8th. Morgan Stanley increased their target price on shares of Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $50.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.80.

Arrowhead Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ ARWR traded up $0.22 during midday trading on Wednesday, hitting $25.22. The stock had a trading volume of 906,027 shares, compared to its average volume of 1,394,640. The stock has a 50 day simple moving average of $26.93 and a 200-day simple moving average of $28.72. The company has a market capitalization of $3.12 billion, a PE ratio of -9.07 and a beta of 0.78. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $20.67 and a 1 year high of $41.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, February 6th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.46). Arrowhead Pharmaceuticals had a negative return on equity of 90.77% and a negative net margin of 163.32%. The business had revenue of $3.55 million for the quarter, compared to analyst estimates of $35.60 million. During the same period last year, the firm earned ($0.39) EPS. The company’s revenue for the quarter was down 94.3% compared to the same quarter last year. As a group, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Hongbo Lu purchased 1,000 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were bought at an average cost of $27.49 per share, for a total transaction of $27,490.00. Following the completion of the purchase, the director now directly owns 31,680 shares of the company’s stock, valued at $870,883.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the sale, the director now owns 30,205 shares of the company’s stock, valued at approximately $704,078.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Hongbo Lu purchased 1,000 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average price of $27.49 per share, with a total value of $27,490.00. Following the purchase, the director now directly owns 31,680 shares of the company’s stock, valued at $870,883.20. The disclosure for this purchase can be found here. Corporate insiders own 4.50% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.